Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on dermatology. Its core business is developing and selling treatments for immune-mediated skin diseases, with ZORYVE as its commercial product platform. The company combines in-house dermatology expertise with a development strategy centered on validated biological targets and differentiated topical and systemic therapies. Arcutis currently operates as a single-reportable-segment business and is building out its own U.S. and Canadian commercialization infrastructure.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePrescription topical products sold under the ZORYVE brand for inflammatory skin diseases.
Revenue from partnering agreements, primarily Sato and Huadong, tied to ex-U.S. development and commercialization rights.
Internal R&D programs for ARQ-234, ARQ-255, and additional ZORYVE label expansions.
Products
Reported · share of revenue- ZORYVE Foam48.9 %
- ZORYVE Cream0.332.5 %
- ZORYVE Cream0.1518.3 %
- ZORYVE Cream0.050.2 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Arcutis sells primarily into the prescription dermatology channel, where dermatologists and allergists prescribe ZORYVE for immune-mediated skin conditions. In the U.S., the company also serves wholesalers and specialty pharmacies that distribute the product to end patients and manage chargebacks, inventory, and reporting. As the company expands into pediatric and primary care settings, it is targeting high-prescribing physicians who can broaden adoption beyond specialist dermatology. In Canada, Arcutis has built commercial infrastructure to support local product launches, while in Asia it relies on partners to reach additional markets.
Core prescribers for ZORYVE who treat plaque psoriasis, seborrheic dermatitis, and atopic dermatitis and value differentiated topical options.
Specialists who prescribe ZORYVE for immune-mediated dermatological conditions, especially atopic dermatitis.
Distribution intermediaries that buy product for channel fulfillment, inventory management, and chargeback administration.
A growing target segment for ZORYVE expansion after the end of the Kowa promotion agreement.
Licensees and collaborators in Japan, China, and other Asian markets that commercialize roflumilast formulations locally.
Strategy
Arcutis is prioritizing commercial execution for ZORYVE while continuing to expand the product's label and reach into additional dermatology settings. The company is shifting more selling responsibility into pediatric and primary care after the Kowa promotion agreement ends, which should broaden the prescriber base beyond dermatology specialists. At the same time, it is focusing clinical development on ARQ-234, ARQ-255, and additional ZORYVE label extensions to extend the franchise. Because Arcutis has no internal manufacturing, it also depends on third parties for supply and must manage partner quality, capacity, and continuity carefully.
A wider prescriber base can increase product uptake and reduce dependence on a narrow specialist channel.
New indications and next-generation assets can extend the life of the franchise and diversify revenue.
Partnering allows Arcutis to access markets without building a full international commercial organization.
Geography
Arcutis is headquartered in Westlake Village, California and conducts its main commercial operations in the United States. The company also has established commercialization infrastructure in Canada, where ZORYVE has been launched in multiple formulations and indications. Outside North America, Arcutis uses partnerships to access markets such as Japan, China, and other countries in Asia rather than building a full direct-sales footprint. Because the company relies on third-party manufacturing and distribution, its geographic exposure is shaped more by commercial launch timing and partner execution than by owned production assets.
Risks
Arcutis remains exposed to the execution risk typical of a commercial-stage biopharmaceutical company with a concentrated product base. Its revenue depends heavily on ZORYVE adoption, reimbursement, and competitive positioning, while generic, OTC, and branded prescription alternatives could pressure demand and pricing. The company also relies on third-party manufacturers, single-source suppliers, and external clinical vendors, so any supply disruption or quality issue could affect launches and product availability. In addition, the company continues to face losses, funding needs, cybersecurity risk, and the possibility that patent protection or litigation outcomes could weaken the franchise over time.
- Patent and generic erosion riskImpact: CriticalLikelihood: Medium
Loss of patent protection or an at-risk generic launch could cause a rapid decline in sales of approved products.
Exposure: Approved ZORYVE products
- Concentration in a small number of commercial productsImpact: HighLikelihood: Medium
The company is still building its dermatology franchise, so ZORYVE performance is central to revenue and operating leverage.
Exposure: ZORYVE cream and foam franchise
- Competitive pressure from existing and new dermatology therapiesImpact: HighLikelihood: Medium
Alternative prescription and OTC products can limit demand, pricing, and reimbursement for ZORYVE.
Exposure - Third-party manufacturing and supply dependenceImpact: HighLikelihood: Medium
The company has no internal manufacturing capabilities and relies on external suppliers for commercial and clinical supply.
Exposure: Commercial supply chain and launch readiness
- Financing and liquidity riskImpact: HighLikelihood: Medium
Continued commercialization and R&D spending may require additional capital if operating cash flow is insufficient.
Exposure - Cybersecurity and data privacy incidentsImpact: MediumLikelihood: Medium
A breach could disrupt operations, damage intellectual property, and create remediation and notification costs.
Exposure
Accounting
Judgemental itemsRevenue is reduced by rebates, chargebacks, prompt pay discounts, distribution fees, and returns, making estimates a key driver of reported sales.
Impact: Can materially affect quarterly revenue and comparability
The company is still refining return assumptions as launch history develops, which can create period-to-period adjustments.
Impact: Affects net revenue and gross-to-net trends
Previously expensed inventory and third-party manufacturing costs can cause margin fluctuations as units are sold.
Impact: Impacts gross margin and quarterly cost of sales
Large NOLs and capitalized research expenses require judgment about realizability.
Impact: Affects tax expense and balance sheet presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Arcturus Therapeutics Holdings Inc.
ARCT · Pharmaceutical Preparations
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Oruka Therapeutics, Inc.
ORKA · Pharmaceutical Preparations
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
Last updated: 24/09/2026